Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00833716 · ClinicalTrials.gov registry record · Phase 1
Effect of Renal Impairment on the Pharmacokinetics of NN9535
A Phase 1 study of Diabetes Mellitus, Type 2 and Diabetes, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 62
- Enrollment target
- 3
- Study locations
NCT00833716 is a Phase 1 study of Diabetes Mellitus, Type 2 and Diabetes that has completed, run by Novo Nordisk A/S. The registered enrollment target is 62 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT00833716, a Phase 1 study of Diabetes Mellitus, Type 2 and Diabetes, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 62 participants
- Enrollment target
- 3
- Study locations
Study Summary
This trial is conducted in the United States of America (USA). The aim of this clinical trial is to investigate how different degrees of renal impairment (mild, moderate, severe and end-stage renal disease) affect the pharmacokinetics of NN9535.
Conditions Studied
Interventions
- DRUG semaglutide
Study Locations (3)
Florida
- Novo Nordisk Investigational Site - Miami
- Novo Nordisk Investigational Site - Orlando
Tennessee
- Novo Nordisk Investigational Site - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2009-02-02 |
| Est. Completion | 2010-07-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00833716
The ClinicalTrials.gov registry entry for NCT00833716 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which semaglutide is the first listed.
NCT00833716 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT00833716 about?
NCT00833716 is a clinical study titled "Effect of Renal Impairment on the Pharmacokinetics of NN9535". This trial is conducted in the United States of America (USA). The aim of this clinical trial is to investigate how different degrees of renal impairment (mild, moderate, severe and end-stage renal disease) affect the pharmacokinetics of NN9535.
What is the current status of trial NCT00833716?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 62 participants. The study started on 2009-02-02. Estimated completion is 2010-07-26.
What conditions does trial NCT00833716 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2, Diabetes, Renal Impairment.
What interventions are being tested in trial NCT00833716?
The interventions under investigation include: semaglutide (DRUG).
Who is sponsoring clinical trial NCT00833716?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00833716 being conducted?
This trial has 3 study locations across Florida, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
RECRUITING · Phase 1
-
Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)
RECRUITING · Phase 1
-
Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans
ACTIVE NOT RECRUITING · Phase 1
-
Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes
ACTIVE NOT RECRUITING · Phase 1
-
A Family Dyad-focused Diabetes Self-Management Intervention for African American Adults
ACTIVE NOT RECRUITING · Phase 1
-
Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.